ATE322249T1 - System zur abgabe einer tobramycin-formulierung - Google Patents

System zur abgabe einer tobramycin-formulierung

Info

Publication number
ATE322249T1
ATE322249T1 AT02771857T AT02771857T ATE322249T1 AT E322249 T1 ATE322249 T1 AT E322249T1 AT 02771857 T AT02771857 T AT 02771857T AT 02771857 T AT02771857 T AT 02771857T AT E322249 T1 ATE322249 T1 AT E322249T1
Authority
AT
Austria
Prior art keywords
delivery system
formulation delivery
tobramycin
less
tobramycin formulation
Prior art date
Application number
AT02771857T
Other languages
English (en)
Inventor
Robert J Speirs
Barbara A Schaeffler
Peter B Challoner
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23123791&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322249(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE322249T1 publication Critical patent/ATE322249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02771857T 2001-05-18 2002-05-17 System zur abgabe einer tobramycin-formulierung ATE322249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18

Publications (1)

Publication Number Publication Date
ATE322249T1 true ATE322249T1 (de) 2006-04-15

Family

ID=23123791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02771857T ATE322249T1 (de) 2001-05-18 2002-05-17 System zur abgabe einer tobramycin-formulierung

Country Status (11)

Country Link
US (8) US20030143162A1 (de)
EP (2) EP1320355B1 (de)
JP (2) JP2004534763A (de)
AT (1) ATE322249T1 (de)
AU (1) AU2010210026A1 (de)
CA (1) CA2447600C (de)
DE (1) DE60210402T2 (de)
DK (1) DK1320355T3 (de)
ES (1) ES2261735T3 (de)
PT (1) PT1320355E (de)
WO (1) WO2002094217A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
PT1320355E (pt) * 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP3738591A3 (de) * 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Neuartige antibakterielle wirkstoffe
US20070071686A1 (en) * 2003-10-15 2007-03-29 Pari Gmbh Liquid preparation containing tobramycin
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
DE602005025754D1 (de) 2004-05-17 2011-02-17 Corus Pharma Inc Kombination aus fosfomycin/aminoglycosid in aerosolform zur behandlung bakterieller atemwegsinfektionen
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20080214481A1 (en) 2004-06-18 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Methods of Treatment of Endobronchial Infections
AU2005306802A1 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
CN104586868A (zh) 2005-09-29 2015-05-06 尼克塔治疗公司 抗生素制剂、单位剂量、试剂盒以及方法
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
PT1962805T (pt) 2005-12-08 2016-10-05 Insmed Inc Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
WO2009055557A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20110049634A1 (en) * 2008-04-02 2011-03-03 Nxp B.V. Method of manufacturing a semiconductor device and semiconductor device
ES2565083T3 (es) * 2008-10-24 2016-03-31 Cempra Pharmaceuticals, Inc. Biodefensas usando macrólidos que contienen triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
MY162411A (en) 2010-03-22 2017-06-15 Cempra Pharmaceuticals Inc Crystalline forms of a macrolide, and uses therefor
SI2571506T1 (sl) 2010-05-20 2017-12-29 Cempra Pharmaceuticals, Inc. Postopki za pripravo makrolidov in ketolidov ter njihovih intermediatov
WO2012007130A1 (en) * 2010-07-12 2012-01-19 Xellia Pharmaceuticals Aps Treatment of lung infections by administration of tobramycin by aerolisation
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
RU2014101763A (ru) 2011-07-12 2015-08-20 Кардис Фарма Корпорейшн Композиции комбинаций амикацина и фосфомицина, способы и системы для лечения вентилятор-ассоциированной пневмонии и вентилятор-ассоциированного трахеоброхита
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
CN105025904A (zh) 2012-09-04 2015-11-04 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
SI2943503T1 (sl) 2013-01-11 2017-11-30 Xellia Pharmaceuticals Aps Polimiksini, sestava, postopki priprave in postopki uporabe
AU2014239959A1 (en) * 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
DK3142643T3 (da) * 2014-05-15 2019-10-14 Insmed Inc Fremgangsmåder til behandling af ikke-tuberkuløse mykobakterielle lungeinfektioner
CN106661090A (zh) 2014-07-09 2017-05-10 埃克斯利亚制药有限公司 低取代的多粘菌素以及它们的组合物
US10532080B2 (en) 2014-10-03 2020-01-14 Xellia Pharmaceuticals Aps Sulfomethylated polymixin compositions
DK3200762T3 (da) 2014-10-03 2019-05-06 Xellia Pharmaceuticals Aps Inhalationsanordning
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
ES2038445T3 (es) 1988-01-28 1993-07-16 Lameplast S.R.L. Tiras de ampollas para productos farmaceuticos, cosmeticos y otros.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
AU778797B2 (en) 1998-12-17 2004-12-23 Novartis Vaccines And Diagnostics, Inc. Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
PT1320355E (pt) 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina

Also Published As

Publication number Publication date
EP1320355B1 (de) 2006-04-05
DE60210402T2 (de) 2006-12-07
US20080095717A1 (en) 2008-04-24
US20030143162A1 (en) 2003-07-31
US20040131555A1 (en) 2004-07-08
PT1320355E (pt) 2006-08-31
CA2447600C (en) 2015-10-20
US8507454B2 (en) 2013-08-13
JP2009269923A (ja) 2009-11-19
US7825095B2 (en) 2010-11-02
AU2010210026A1 (en) 2010-09-02
US20050207987A1 (en) 2005-09-22
US20040265241A1 (en) 2004-12-30
WO2002094217A1 (en) 2002-11-28
US20110005518A1 (en) 2011-01-13
US20050201947A1 (en) 2005-09-15
US20120101055A1 (en) 2012-04-26
EP2186508A3 (de) 2010-08-25
EP1320355A1 (de) 2003-06-25
DE60210402D1 (de) 2006-05-18
EP2186508A2 (de) 2010-05-19
JP2004534763A (ja) 2004-11-18
CA2447600A1 (en) 2002-11-28
ES2261735T3 (es) 2006-11-16
DK1320355T3 (da) 2006-07-31
US6890907B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
ATE322249T1 (de) System zur abgabe einer tobramycin-formulierung
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
NZ552047A (en) Method of treatment of endobronchial infections
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
BR0109875A (pt) Tratamento de doenças respiratórias
EP0861667A3 (de) Partikelförmige Mittel
EP3268010B1 (de) Zusammensetzungen aus gesäuertem nitrit, einem eisen-chelator und einem antibakteriellen wirkstoff zur behandlung von bakterieninfektionen
MXPA03000353A (es) Medicamentos para tratamiento quimioterapeutico de enfermedades.
IL101056A (en) Composition for nasal treatment
MY144021A (en) Pharmaceutical delivery system
AU644094B2 (en) Medicaments
MXPA03000321A (es) Formulaciones de macrolido para inhalacion y metodos de tratamiento de infecciones endobronquiales.
MXPA05009629A (es) Composiciones que contienen trospio.
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
DK98089D0 (da) Medikament-lipid-systemer med lav toxicitet
WO2005037256A3 (de) Flüssige zubereitung enthaltend tobramycin
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
NO20041011L (no) Inhaleringssammensetninger omfattende tricykliske 5,6-dihydro-9H-pyrazolo(3,4-C) -1,2,4-triazolo(4,3-alfa)pyridiner
AU2615795A (en) Compounds and compositions for administration via oral inhalation or insufflation
AU2002236587A1 (en) Compositions for adhesion prevention
WO2002074287A3 (en) Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics
EP0753309A2 (de) Lactoferrin (oder analoge Proteine) und Desferrioxamine-Methansulfonate (oder andere Metalionenchelaten) Zusammensetzung für Therapie von viralen infektiösen Krankheiten
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
KR20090042507A (ko) 돼지 위축성 비염의 예방 및 치료를 위해 아미카신 및 이의약제학적으로 허용가능한 염과, 베타-글루칸을 유효성분을포함하는 비강 분무용 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320355

Country of ref document: EP